ABP 938
Laufzeit: 01.01.2021 - 31.12.2022
Kurzfassung
A Randomized, Double-masked, Phase 3 Study of ABP 938 Efficacy and Safety Compared to Aflibercept (Eylea) in Subjects with Neovascular Age-related Macular Degeneration
Laufzeit: 01.01.2021 - 31.12.2022
A Randomized, Double-masked, Phase 3 Study of ABP 938 Efficacy and Safety Compared to Aflibercept (Eylea) in Subjects with Neovascular Age-related Macular Degeneration
